These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33175579)

  • 1. Radiologic findings and the molecular expression profile of diffuse midline glioma H3 K27M mutant.
    Seong M; Kim ST; Noh JH; Kim YK; Kim HJ
    Acta Radiol; 2021 Oct; 62(10):1404-1411. PubMed ID: 33175579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements.
    Chen H; Hu W; He H; Yang Y; Wen G; Lv X
    Eur J Radiol; 2019 May; 114():152-159. PubMed ID: 31005167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis.
    Aboian MS; Tong E; Solomon DA; Kline C; Gautam A; Vardapetyan A; Tamrazi B; Li Y; Jordan CD; Felton E; Weinberg B; Braunstein S; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2019 Nov; 40(11):1804-1810. PubMed ID: 31694820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.
    Aboian MS; Solomon DA; Felton E; Mabray MC; Villanueva-Meyer JE; Mueller S; Cha S
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):795-800. PubMed ID: 28183840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
    Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
    Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
    Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
    [No Abstract]   [Full Text] [Related]  

  • 7. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
    Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
    J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending the Neuroanatomic Territory of Diffuse Midline Glioma, K27M Mutant: Pineal Region Origin.
    Gilbert AR; Zaky W; Gokden M; Fuller CE; Ocal E; Leeds NE; Fuller GN
    Pediatr Neurosurg; 2018; 53(1):59-63. PubMed ID: 29131126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
    Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
    J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion and perfusion imaging biomarkers of H3 K27M mutation status in diffuse midline gliomas.
    Kathrani N; Chauhan RS; Kotwal A; Kulanthaivelu K; Bhat MD; Saini J; Prasad C; Chakrabarti D; Santosh V; Uppar AM; Srinivas D
    Neuroradiology; 2022 Aug; 64(8):1519-1528. PubMed ID: 35083503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced MR imaging and
    Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures.
    Banan R; Akbarian A; Samii M; Samii A; Bertalanffy H; Lehmann U; Hartmann C; Brüning R
    PLoS One; 2021; 16(8):e0249647. PubMed ID: 34347774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter clinical radiomics-integrated model based on [
    Zhang L; Pan H; Liu Z; Gao J; Xu X; Wang L; Wang J; Tang Y; Cao X; Kan Y; Wen Z; Chen J; Huang D; Chen S; Li Y
    Eur Radiol; 2023 Feb; 33(2):872-883. PubMed ID: 35984514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
    Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
    Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping glioma heterogeneity using multiparametric 18 F-choline PET/MRI in childhood and teenage-young adults.
    Ferrazzoli V; Shankar A; Cockle JV; Tang C; Al-Khayfawee A; Bomanji J; Fraioli F; Hyare H
    Nucl Med Commun; 2023 Jan; 44(1):91-99. PubMed ID: 36378239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
    Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
    Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
    Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
    Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.